Kynurenine pathway metabolites and suicidality

Neuropharmacology

Volumn 112, Issue , 2017, Pages 324-330

  Bryleva, Elena Y ^a   Brundin, Lena ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Cytokine; Depression; Glutamate; Inflammation; Kynurenine pathway; Quinolinic acid

Indexed keywords

3 HYDROXYANTHRANILIC ACID; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; KYNURENIC ACID; KYNURENINE; PICOLINIC ACID; QUINOLINIC ACID; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; CYTOKINE;

DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; INFLAMMATION; METABOLITE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUICIDAL BEHAVIOR; SUICIDE; ANIMAL; BLOOD; METABOLISM; PHYSIOLOGY;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; KYNURENINE; METABOLIC NETWORKS AND PATHWAYS; SUICIDE;

EID: 84956660820     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.01.034     Document Type: Review

References (94)

1. Abdallah, C.G., Sanacora, G., Duman, R.S., Krystal, J.H., Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 66 (2015), 509–523.
2. Asberg, M., Traskman, L., Thoren, P., 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor?. Arch. Gen. Psychiatry 33 (1976), 1193–1197.
3. Bach, H., Arango, V., Neuroanatomy of serotonergic abnormalities in suicide. Dwivedi, Y., (eds.) The Neurobiological Basis of Suicide, Boca Raton (FL), 2012.
4. Baldessarini, R.J., Tondo, L., Davis, P., Pompili, M., Goodwin, F.K., Hennen, J., Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 8 (2006), 625–639.
5. Baran, H., Schwarcz, R., Presence of 3-hydroxyanthranilic acid in rat tissues and evidence for its production from anthranilic acid in the brain. J. Neurochem. 55 (1990), 738–744.
6. Bay-Richter, C., Linderholm, K.R., Lim, C.K., Samuelsson, M., Traskman-Bendz, L., Guillemin, G.J., Erhardt, S., Brundin, L., A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav. Immun. 43 (2015), 110–117.
7. Beninger, R.J., Colton, A.M., Ingles, J.L., Jhamandas, K., Boegman, R.J., Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neuroscience 61 (1994), 603–612.
8. Bradley, K.A., Case, J.A., Khan, O., Ricart, T., Hanna, A., Alonso, C.M., Gabbay, V., The role of the kynurenine pathway in suicidality in adolescent major depressive disorder. Psychiatry Res. 227 (2015), 206–212.
9. Busse, M., Busse, S., Myint, A.M., Gos, T., Dobrowolny, H., Muller, U.J., Bogerts, B., Bernstein, H.G., Steiner, J., Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses?. Eur. Arch. Psychiatry Clin. Neurosci. 265 (2015), 321–329.
10. Carlborg, A., Jokinen, J., Jonsson, E.G., Erhardt, S., Nordstrom, P., CSF kynurenic acid and suicide risk in schizophrenia spectrum psychosis. Psychiatry Res. 205 (2013), 165–167.
11. Centers for Disease Control and Prevention, Cost of Injury Reports. 2010.
12. Chen, Y., Brew, B.J., Guillemin, G.J., Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis. J. Neurochem. 118 (2011), 816–825.
13. Christen, S., Peterhans, E., Stocker, R., Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 2506–2510.
14. Claes, S., Myint, A.M., Domschke, K., Del-Favero, J., Entrich, K., Engelborghs, S., De Deyn, P., Mueller, N., Baune, B., Rothermundt, M., The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. Psychiatry Res. 188 (2011), 355–360.
15. Cockhill, J., Jhamandas, K., Boegman, R.J., Beninger, R.J., Action of picolinic acid and structurally related pyridine carboxylic acids on quinolinic acid-induced cortical cholinergic damage. Brain Res. 599 (1992), 57–63.
16. Coggan, S.E., Smythe, G.A., Bilgin, A., Grant, R.S., Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid. J. Neurochem. 108 (2009), 1220–1225.
17. Da Cruz, D., Pearson, A., Saini, P., Miles, C., While, D., Swinson, N., Williams, A., Shaw, J., Appleby, L., Kapur, N., Emergency department contact prior to suicide in mental health patients. Emerg. Med. J. EMJ 28 (2011), 467–471.
18. Darlington, L.G., Forrest, C.M., Mackay, G.M., Smith, R.A., Smith, A.J., Stoy, N., Stone, T.W., On the biological importance of the 3-hydroxyanthranilic acid: anthranilic acid ratio. Int. J. Tryptophan Res. IJTR 3 (2010), 51–59.
19. David Klonsky, E., Kotov, R., Bakst, S., Rabinowitz, J., Bromet, E.J., Hopelessness as a predictor of attempted suicide among first admission patients with psychosis: a 10-year cohort study. Suicide Life-threat. Behav. 42 (2012), 1–10.
20. Davidson, J.R., Abraham, K., Connor, K.M., McLeod, M.N., Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol. Psychiatry 53 (2003), 261–264.
21. de Carvalho, L.P., Bochet, P., Rossier, J., The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem. Int. 28 (1996), 445–452.
22. DiazGranados, N., Ibrahim, L.A., Brutsche, N.E., Ameli, R., Henter, I.D., Luckenbaugh, D.A., Machado-Vieira, R., Zarate, C.A. Jr., Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 71 (2010), 1605–1611.
23. Docherty, J.P., Sack, D.A., Roffman, M., Finch, M., Komorowski, J.R., A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J. Psychiatr. Pract. 11 (2005), 302–314.
24. Du, F., Schmidt, W., Okuno, E., Kido, R., Kohler, C., Schwarcz, R., Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J. Comp. Neurol. 321 (1992), 477–487.
25. Dubey, V.K., Ansari, F., Vohora, D., Khanam, R., Possible involvement of corticosterone and serotonin in antidepressant and antianxiety effects of chromium picolinate in chronic unpredictable mild stress induced depression and anxiety in rats. J. Trace Elem. Med. Biol. Organ Soc. Miner. Trace Elem. 29 (2015), 222–226.
26. Dumais, A., Lesage, A.D., Alda, M., Rouleau, G., Dumont, M., Chawky, N., Roy, M., Mann, J.J., Benkelfat, C., Turecki, G., Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am. J. Psychiatry 162 (2005), 2116–2124.
27. Egashira, Y., Sato, M., Saito, K., Sanada, H., Dietary protein level and dietary interaction affect quinolinic acid concentration in rats. Int. J. Vitam. Nutr. Res. Int. Z. Vitam. Ernahr. J. Int. Vitaminol. Nutr. 77 (2007), 142–148.
28. Erhardt, S., Lim, C.K., Linderholm, K.R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T.T., Traskman-Bendz, L., Guillemin, G.J., Brundin, L., Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 38 (2013), 743–752.
29. Erhardt, S., Olsson, S.K., Engberg, G., Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS drugs 23 (2009), 91–101.
30. Erhardt, S., Schwieler, L., Engberg, G., Kynurenic acid and schizophrenia. Adv. Exp. Med. Biol. 527 (2003), 155–165.
31. Espey, M.G., Chernyshev, O.N., Reinhard, J.F. Jr., Namboodiri, M.A., Colton, C.A., Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 8 (1997), 431–434.
32. Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lancon, C., Brittner, M., Micoulaud-Franchi, J.A., Richieri, R., Courtet, P., Abbar, M., Roger, M., Leboyer, M., Boyer, L., Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology 231 (2014), 3663–3676.
33. Fukuoka, S., Ishiguro, K., Tanabe, A., Egashira, Y., Sanada, H., Fukuwatari, T., Shibata, K., Identification and expression of alpha cDNA encoding human 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD): a key enzyme for the tryptophan-niacine pathway and quinolinate hypothesis. Adv. Exp. Med. Biol. 527 (2003), 443–453.
34. Fukuwatari, T., Ohsaki, S., Fukuoka, S., Sasaki, R., Shibata, K., Phthalate esters enhance quinolinate production by inhibiting alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD), a key enzyme of the tryptophan pathway. Toxicol. Sci. Off. J. Soc. Toxicol. 81 (2004), 302–308.
35. Fukuwatari, T., Sugimoto, E., Shibata, K., Growth-promoting activity of pyrazinoic acid, a putative active compound of antituberculosis drug pyrazinamide, in niacin-deficient rats through the inhibition of ACMSD activity. Biosci. Biotechnol. Biochem. 66 (2002), 1435–1441.
36. Gabbay, V., Klein, R.G., Katz, Y., Mendoza, S., Guttman, L.E., Alonso, C.M., Babb, J.S., Hirsch, G.S., Liebes, L., The possible role of the kynurenine pathway in adolescent depression with melancholic features. J. Child Psychol. Psychiatry Allied Discip. 51 (2010), 935–943.
37. Gabbay, V., Liebes, L., Katz, Y., Liu, S., Mendoza, S., Babb, J.S., Klein, R.G., Gonen, O., The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog. Neuro-psychopharmacol. Biol. Psychiatry 34 (2010), 37–44.
38. Goda, K., Kishimoto, R., Shimizu, S., Hamane, Y., Ueda, M., Quinolinic acid and active oxygens. Possible contribution of active oxygens during cell death in the brain. Adv. Exp. Med. Biol. 398 (1996), 247–254.
39. Goldstein, L.E., Leopold, M.C., Huang, X., Atwood, C.S., Saunders, A.J., Hartshorn, M., Lim, J.T., Faget, K.Y., Muffat, J.A., Scarpa, R.C., Chylack, L.T. Jr., Bowden, E.F., Tanzi, R.E., Bush, A.I., 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry 39 (2000), 7266–7275.
40. Grant, R.S., Coggan, S.E., Smythe, G.A., The physiological action of picolinic acid in the human brain. Int. J. Tryptophan Res. IJTR 2 (2009), 71–79.
41. Gray, A.L., Hyde, T.M., Deep-Soboslay, A., Kleinman, J.E., Sodhi, M.S., Sex differences in glutamate receptor gene expression in major depression and suicide. Mol. Psychiatry 20 (2015), 1057–1068.
42. Guillemin, G.J., Quinolinic acid, the inescapable neurotoxin. FEBS J. 279 (2012), 1356–1365.
43. Guillemin, G.J., Quinolinic acid: neurotoxicity. FEBS J., 279, 2012, 1355.
44. Guillemin, G.J., Cullen, K.M., Lim, C.K., Smythe, G.A., Garner, B., Kapoor, V., Takikawa, O., Brew, B.J., Characterization of the kynurenine pathway in human neurons. J. Neurosci. Off. J. Soc. Neurosci. 27 (2007), 12884–12892.
45. Guillemin, G.J., Kerr, S.J., Smythe, G.A., Smith, D.G., Kapoor, V., Armati, P.J., Croitoru, J., Brew, B.J., Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78 (2001), 842–853.
46. Guillemin, G.J., Smith, D.G., Smythe, G.A., Armati, P.J., Brew, B.J., Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv. Exp. Med. Biol. 527 (2003), 105–112.
47. Guzzetta, F., Tondo, L., Centorrino, F., Baldessarini, R.J., Lithium treatment reduces suicide risk in recurrent major depressive disorder. J. Clin. Psychiatry 68 (2007), 380–383.
48. Hardeland, R., Zsizsik, B.K., Poeggeler, B., Fuhrberg, B., Holst, S., Coto-Montes, A., Indole-3-pyruvic and -propionic acids, kynurenic acid, and related metabolites as luminophores and free-radical scavengers. Adv. Exp. Med. Biol. 467 (1999), 389–395.
49. Harris, E.C., Barraclough, B., Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry 170 (1997), 205–228.
50. Hawton, K., van Heeringen, K., Suicide. Lancet 373 (2009), 1372–1381.
51. Heyes, M.P., Achim, C.L., Wiley, C.A., Major, E.O., Saito, K., Markey, S.P., Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320:Pt 2 (1996), 595–597.
52. Hughes, M.M., Carballedo, A., McLoughlin, D.M., Amico, F., Harkin, A., Frodl, T., Connor, T.J., Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav. Immun. 26 (2012), 979–987.
53. Ibrahim, L., Diazgranados, N., Franco-Chaves, J., Brutsche, N., Henter, I.D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D.A., Manji, H.K., Zarate, C.A. Jr., Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 37 (2012), 1526–1533.
54. Jhamandas, K.H., Boegman, R.J., Beninger, R.J., Flesher, S., Role of zinc in blockade of excitotoxic action of quinolinic acid by picolinic acid. Amino Acids 14 (1998), 257–261.
55. Kang, H.J., Kim, J.M., Lee, J.Y., Kim, S.Y., Bae, K.Y., Kim, S.W., Shin, I.S., Kim, H.R., Shin, M.G., Yoon, J.S., BDNF promoter methylation and suicidal behavior in depressive patients. J. Affect. Disord. 151 (2013), 679–685.
56. Kennedy, S.H., Milev, R., Giacobbe, P., Ramasubbu, R., Lam, R.W., Parikh, S.V., Patten, S.B., Ravindran, A.V., Canadian Network for, M., Anxiety, T, Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J. Affect. Disord. 117:Suppl. 1 (2009), S44–S53.
57. Kim, J.M., Kang, H.J., Bae, K.Y., Kim, S.W., Shin, I.S., Kim, H.R., Shin, M.G., Yoon, J.S., Association of BDNF promoter methylation and genotype with suicidal ideation in elderly Koreans. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry 22 (2014), 989–996.
58. Larkin, G.L., Beautrais, A.L., A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int. J. Neuropsychopharmacol. 14 (2011), 1127–1131.
59. Leenaars, A.A., Suicide notes, communication, and ideation. M, R.W., Berman, A.L., Maltsberger, J.T., Yufit, R.I., (eds.) Assessment and Prediction of Suicide, 1992, The Guilford press, New York.
60. Leklem, J.E., Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am. J. Clin. Nutr. 24 (1971), 659–672.
61. Linderholm, K.R., Skogh, E., Olsson, S.K., Dahl, M.L., Holtze, M., Engberg, G., Samuelsson, M., Erhardt, S., Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 38 (2012), 426–432.
62. Lockwood, L.E., Su, S., Youssef, N.A., The role of epigenetics in depression and suicide: a platform for gene-environment interactions. Psychiatry Res. 228 (2015), 235–242.
63. Lugo-Huitron, R., Blanco-Ayala, T., Ugalde-Muniz, P., Carrillo-Mora, P., Pedraza-Chaverri, J., Silva-Adaya, D., Maldonado, P.D., Torres, I., Pinzon, E., Ortiz-Islas, E., Lopez, T., Garcia, E., Pineda, B., Torres-Ramos, M., Santamaria, A., La Cruz, V.P., On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol. Teratol. 33 (2011), 538–547.
64. Maes, M., Leonard, B.E., Myint, A.M., Kubera, M., Verkerk, R., The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuro-psychopharmacol. Biol. Psychiatry 35 (2011), 702–721.
65. Mann, J.J., Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 4 (2003), 819–828.
66. McGuffin, P., Perroud, N., Uher, R., Butler, A., Aitchison, K.J., Craig, I., Lewis, C., Farmer, A., The genetics of affective disorder and suicide. Eur. Psychiatry J. Assoc. Eur. Psychiatr. 25 (2010), 275–277.
67. McLeod, M.N., Gaynes, B.N., Golden, R.N., Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J. Clin. Psychiatry 60 (1999), 237–240.
68. Meltzer, H.Y., Baldessarini, R.J., Reducing the risk for suicide in schizophrenia and affective disorders. J. Clin. Psychiatry 64 (2003), 1122–1129.
69. Moroni, F., Cozzi, A., Sili, M., Mannaioni, G., Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J. Neural Transm. 119 (2012), 133–139.
70. Mortality, G.B.D., Causes of Death, C., Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
71. Myint, A.M., Kim, Y.K., Verkerk, R., Scharpe, S., Steinbusch, H., Leonard, B., Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98 (2007), 143–151.
72. O'Connor, J.C., Lawson, M.A., Andre, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14 (2009), 511–522.
73. Perroud, N., Baud, P., Mouthon, D., Courtet, P., Malafosse, A., Impulsivity, aggression and suicidal behavior in unipolar and bipolar disorders. J. Affect. Disord. 134 (2011), 112–118.
74. Price, R.B., Mathew, S.J., Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs 29 (2015), 181–188.
75. Price, R.B., Nock, M.K., Charney, D.S., Mathew, S.J., Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66 (2009), 522–526.
76. Pucci, L., Perozzi, S., Cimadamore, F., Orsomando, G., Raffaelli, N., Tissue expression and biochemical characterization of human 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism. FEBS J. 274 (2007), 827–840.
77. Roy, A., Sarchiopone, M., Carli, V., Gene-environment interaction and suicidal behavior. J. Psychiatr. Pract. 15 (2009), 282–288.
78. Savitz, J., Drevets, W.C., Wurfel, B.E., Ford, B.N., Bellgowan, P.S., Victor, T.A., Bodurka, J., Teague, T.K., Dantzer, R., Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav. Immun. 46 (2015), 55–59.
79. Schwarcz, R., Bruno, J.P., Muchowski, P.J., Wu, H.Q., Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13 (2012), 465–477.
80. Schwieler, L., Larsson, M.K., Skogh, E., Kegel, M.E., Orhan, F., Abdelmoaty, S., Finn, A., Bhat, M., Samuelsson, M., Lundberg, K., Dahl, M.L., Sellgren, C., Schuppe-Koistinen, I., Svensson, C., Erhardt, S., Engberg, G., Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia–significance for activation of the kynurenine pathway. J. Psychiatry Neurosci. JPN 40 (2015), 126–133.
81. Steiner, J., Walter, M., Gos, T., Guillemin, G.J., Bernstein, H.G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., Meyer zu Schwabedissen, L., Bogerts, B., Myint, A.M., Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J. Neuroinflamm., 8, 2011, 94.
82. Stipek, S., Stastny, F., Platenik, J., Crkovska, J., Zima, T., The effect of quinolinate on rat brain lipid peroxidation is dependent on iron. Neurochem. Int. 30 (1997), 233–237.
83. Stone, T.W., Stoy, N., Darlington, L.G., An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci. 34 (2013), 136–143.
84. Sublette, M.E., Galfalvy, H.C., Fuchs, D., Lapidus, M., Grunebaum, M.F., Oquendo, M.A., Mann, J.J., Postolache, T.T., Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav. Immun. 25 (2011), 1272–1278.
85. Urata, Y., Koga, K., Hirota, Y., Akiyama, I., Izumi, G., Takamura, M., Nagai, M., Harada, M., Hirata, T., Yoshino, O., Kawana, K., Fujii, T., Osuga, Y., IL-1beta increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells. Am. J. Reprod. Immunol. 72 (2014), 496–503.
86. van Heeringen, K., Bijttebier, S., Desmyter, S., Vervaet, M., Baeken, C., Is there a neuroanatomical basis of the vulnerability to suicidal behavior? A coordinate-based meta-analysis of structural and functional MRI studies. Front. Hum. Neurosci., 8, 2014, 824.
87. Varnik, P., Suicide in the world. Int. J. Environ. Res. Public Health 9 (2012), 760–771.
88. Walker, A.K., Budac, D.P., Bisulco, S., Lee, A.W., Smith, R.A., Beenders, B., Kelley, K.W., Dantzer, R., NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 38 (2013), 1609–1616.
89. Wang, X., Davis, I., Liu, A., Miller, A., Shamsi, S.A., Improved separation and detection of picolinic acid and quinolinic acid by capillary electrophoresis-mass spectrometry: application to analysis of human cerebrospinal fluid. J. Chromatogr. A 1316 (2013), 147–153.
90. Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., Carli, V., European Psychiatric, A., The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur. Psychiatry J. Assoc. Eur. Psychiatr. 27 (2012), 129–141.
91. Wejksza, K., Rzeski, W., Okuno, E., Kandefer-Szerszen, M., Albrecht, J., Turski, W.A., Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in oligodendrocyte cell line (OLN-93). Neurochem. Res. 30 (2005), 963–968.
92. World Health Organization, Preventing Suicide: a Global Imperative. 2014 Geneva.
93. Zarate, C., Duman, R.S., Liu, G., Sartori, S., Quiroz, J., Murck, H., New paradigms for treatment-resistant depression. Ann. N. Y. Acad. Sci. 1292 (2013), 21–31.
94. Zarate, C.A. Jr., Brutsche, N.E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C.A., Liberty, V., Luckenbaugh, D.A., Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71 (2012), 939–946.